Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Laboratory Corporation of America Holdings(LH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LH
10/23/2026: LH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Laboratory Corporation of America Holdings is a major provider of clinical laboratory services and biopharmaceutical drug development support. The company maintains a leading position in the diagnostic market, supported by a vast, scalable laboratory network that drives operational efficiency. Its investment story centers on the integration of testing with data-rich clinical research to capture growth in personalized medicine. However, the company faces persistent risks from reimbursement pressures and intense competition from large rivals and hospital labs. Suitable for investors seeking exposure to the healthcare services sector, the stock is a long-term play on diagnostic volume and pharmaceutical outsourcing, with investors monitoring legislative trends and margin sustainability closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company provides steady growth in life sciences but lacks the explosive growth profile of early-stage tech. |
| Momentum investor | Weak fit | The stock typically exhibits slower, long-term movement rather than the high-volatility spikes sought by momentum strategies. |
| Value investor | Strong fit | Consistent cash flows and stable market positioning often make it attractive to value-oriented investors. |
| Dividend investor | Mixed fit | The company pays a dividend but is primarily focused on capital reinvestment and growth. |
| Low-risk investor | Strong fit while signal remains positive | As a stable healthcare utility, it generally offers lower volatility than pure-play biotech or medical tech stocks. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Healthcare stocks can be sensitive to legislative and reimbursement news. |
| Valuation risk | Medium | Market pricing often fluctuates based on broader economic growth expectations. |
| Competition risk (diagnostics/CRO) | Medium / high | The market is highly saturated with large-scale competitors fighting for physician and pharma contracts. |
| Business quality | Strong | The company maintains a high-quality, essential service business model. |
| Dividend income | Low | Income generation is secondary to growth and reinvestment objectives. |
| Execution risk | Medium | Integrating large acquisitions and managing complex laboratory logistics remains a core operational challenge. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 9.28% | Avg. Invested days 42 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 26.68B USD | Price to earnings Ratio 27.21 | 1Y Target Price 345.12 |
Price to earnings Ratio 27.21 | 1Y Target Price 345.12 | ||
Volume (30-day avg) 740.3K shares | Beta 0.85 | 52 Weeks Range 242.07 - 341.06 | Updated Date 10/24/2026 |
52 Weeks Range 242.07 - 341.06 | Updated Date 10/24/2026 | ||
Dividends yield (FY) 0.87% | Basic EPS (TTM) 12.09 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostics | Clinical laboratory testing services for physicians and patients. | The company makes money every time a routine or specialized blood test is processed in its labs. |
| Biopharma Laboratory Services | Drug development, clinical trials, and research support. | The company is paid by drug developers to handle the technical and research-heavy parts of bringing new medicines to market. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When Before Market | Estimate 4.65 | Actual - |
Profitability
Profit Margin 6.99% | Operating Margin (TTM) 12.24% |
Management Effectiveness
Return on Assets (TTM) 5.53% | Return on Equity (TTM) 11.73% |
Valuation
Trailing PE 27.21 | Forward PE 16.16 | Enterprise Value 32.80B | Price to Sales(TTM) 1.86 |
Enterprise Value 32.80B | Price to Sales(TTM) 1.86 | ||
Enterprise Value to Revenue 2.22 | Enterprise Value to EBITDA 14.78 | Shares Outstanding 81.10M | Shares Floating 80.72M |
Shares Outstanding 81.10M | Shares Floating 80.72M | ||
Percent Insiders 0.35 | Percent Institutions 101.39 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.